• français
    • English
  • français 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation

Thumbnail
Date
2013
Dewey
Economie sociale
Sujet
Competition strategy; product portfolio; re-innovation; super generics; technology platforms
JEL code
I.I1.I12; O.O3.O32; L.L6.L65
Journal issue
GaBI Journal
Volume
2
Number
1
Publication date
03-2013
Publisher
Generics and Biosimilars Initiative (GaBI)
DOI
http://dx.doi.org/10.5639/gabij.2013.0201.011
URI
https://basepub.dauphine.fr/handle/123456789/11197
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Barei, Fereshteh
status unknown
Le Pen, Claude
status unknown
Simoens, Steven
status unknown
Type
Article accepté pour publication ou publié
Abstract (EN)
Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself. Objective: The objective of this article is to gain insight into the re-innovation model in some of the innovative generic pharmaceutical firms. To this effect, we show how some of the generic pharmaceutical firms attempt to achieve competitive advantages either by improving existing product attributes or by replacing new components, reshaping their configuration, and using new technology platforms to produce new innovative products. Methods: We used a qualitative method to examine re-innovation at several levels within these companies, in their management systems, business models and product portfolios. The research was conducted by a series of semi-structured interviews with chief executive officers (CEOs), consultants, researchers, patent attorneys, pharmacists and medics in different countries. Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets. Conclusions: A new approach to innovativeness together with a value proposition strategy aims to deliver high quality products to patients.

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.